{"success":true,"data":{"pressRelease":{"id":"37870","rtpr_id":"nGNX24Hxnf","ticker":"EBS","exchange":"NYSE","all_tickers":["EBS"],"title":"Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]","author":"Globe Newswire","published_at":"2026-05-18T12:59:00.141Z","article_body":"GAITHERSBURG, Md., May 18, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions\n(NYSE:EBS), a global biodefense company, today announced that the Saudi Food\nand Drug Authority (SFDA) has approved the registration of ACAM2000®\n[Smallpox and Mpox  (Vaccinia) Vaccine, Live], for the prevention of smallpox\nand mpox disease in individuals determined to be at high risk for smallpox or\nmpox infection. This follows Emergent’s recent announcement\n(https://www.globenewswire.com/Tracker?data=Ea8TQEEr3uSK98w44E2YjD_jnv2GcxLHG-QPV9jwPHROX2pCu0ImUT8SFY8OX9LGx5F24dcSRrCybRo4W9HKGqait_16aRXZg3zuEfVizOsBBLFsM_frOjrpgVF6RC2XtB2Hht1zpnhfuyz6s9d02pRSHdUfoO3IpFHG-LHPVAWSCHsN19rzqshbbbn-3PU3W6Qvv4zZ0-BJXxn0EWn0rR89X9oe84-k5q-0hTy8p3U=)\nthat Singapore’s Health Sciences Authority (HSA) has approved an expanded\nindication for ACAM2000(® )[Smallpox and Mpox (Vaccinia) Vaccine, Live] to\ninclude prevention of mpox disease in adults determined to be at high risk for\nmpox infection.\n\n“We are pleased to receive this approval for ACAM2000(®) from SFDA for\nimmunization against smallpox and mpox in high-risk individuals,” said Simon\nLowry, chief medical officer of Emergent. “ACAM2000(®) is the first\nEmergent product to be licensed by the SFDA and demonstrates the company’s\nintent to collaborate with governments in the Gulf region and around the world\nas awareness and adoption of biodefense preparedness strategies continues to\nincrease around the world.”\n\nSmallpox is considered a credible bioterror threat by experts, and its\nmortality makes it a potential high-impact threat with health, economic and\nnational security implications.(1 )Mpox virus is part of the same family of\nviruses as variola virus, the virus that causes smallpox. Since the start of\nthe global outbreak of mpox in 2022, there have been more than 137,000\nconfirmed cases and more than 300 deaths reported globally.(2)\n\nEmergent specializes in developing, manufacturing and delivering medical\ncountermeasures to governments around the world for national security and\nhealth preparedness. These products support how governments respond to\nemergencies and help protect the public from potential threats like smallpox,\nmpox, anthrax and botulism.\n\nIndication and Select Important Safety Information for ACAM2000(®) [Smallpox\nand Mpox (Vaccinia) Vaccine, Live]\nIndication\nACAM2000(®) is indicated for active immunization for the prevention of\nsmallpox and mpox disease in individuals determined to be at high risk for\nsmallpox or mpox infection.\n\nImportant Safety Information \nWarning: Serious Complications \nMyocarditis and pericarditis (suspect cases observed at a rate of 5.7 per 1000\nprimary vaccinees (95% CI: 1.9-13.3)), encephalitis, encephalomyelitis,\nencephalopathy, progressive vaccinia, generalized vaccinia, severe vaccinial\nskin infections, erythema multiforme major (including STEVENS-JOHNSON\nSYNDROME), eczema vaccinatum resulting in permanent sequelae or death,\naccidental eye infection (ocular vaccinia) which can cause ocular\ncomplications that may lead to blindness, and fetal death, have occurred\nfollowing either primary vaccination or revaccination with ACAM2000(®) or\nother live vaccinia virus vaccines that were used historically.\n\nContraindications\nDo not administer ACAM2000(®) to individuals with severe immunodeficiency.\nThese individuals may include persons who are undergoing bone marrow\ntransplantation or persons with primary or acquired immunodeficiency states\nwho require isolation.\n\nWarnings and Precautions\nSerious complications that may follow either primary or revaccination with\nACAM2000(®) include myocarditis and/or pericarditis, ischemic heart disease\nand non-ischemic dilated cardiomyopathy, encephalitis, encephalomyelitis,\nencephalopathy, progressive vaccinia (vaccinia necrosum), generalized\nvaccinia, severe vaccinial skin infections, erythema multiforme major\n(including Stevens-Johnson syndrome), eczema vaccinatum, fetal at\n1-877-246-8472 (U.S.), 1-800-768-2304 (Canada), or\nmedicalinformation@ebsi.com; or VAERS at 1-800-822-7967 or\nhttps://vaers.hhs.gov. Please see the full Prescribing Information\n(https://www.globenewswire.com/Tracker?data=HTifwnnS7SElnnsT0I5k7GtroTSSlB9fCV32WQZldwhYg8YXM-_mTqUgQ9WobUHzQ2h8M_7EefK08wDsRUfR7Np3bkVN74K4Rb9Rvl5ap-foOSaZXyyMc68bxEVDhRWchN5UdV0KpTmHPT1TsGghzMEMSiizUNSrSXgQOsKErk1VMqUzlRo7VybELanCbXWMUaXe1BDWQKq7VGscHYVZdy2Rkc6Cq1c121a7UjpX9zqhbBwvmdXOhs51prMgXwh0)\nfor ACAM2000(®) for complete Boxed Warning and safety information.\n\nAbout Emergent BioSolutions\nAt Emergent, our mission is to protect and save lives. For over 25\nyears, we’ve been at work preparing those entrusted with protecting public\nhealth. We deliver protective and life-saving solutions for health threats\nlike smallpox, mpox, botulism, Ebola, anthrax and opioid overdose\nemergencies. To learn more about how we help prepare communities around the\nworld for today’s health challenges and tomorrow’s threats, visit\nour website\n(https://www.globenewswire.com/Tracker?data=UDYUkxCarH-pcCWkjxjsT-7j6PYLxwcQcEVGLeGWrnEE14guzpUQ_PQbuEx55aCTwDSlgGyMflxzVk08jYPZdqRZalvm7emvYrta8uALHJzl8uBjUTqfC5Cwmu_xtGEK5tjWgMrlIenQyv7wOsdwOe2eHHP471AA8pfh7xZaVxHV8ipaO4Vx-CWmziDYqNOXR6PCrYvmIpwg3YongOmARHxXkIhC7PvduAqF14WLQamupiqDdwfHk5Dh90WpcVvAJ9wZnYN_yogp-dDkSjR4qSFhIO5ToWwmTnrKkcz3Cy3Iu8u0EQFkPjKWxUUa1d97Fld-TdAHM_K9VnB9riSGUSZSxlVaSwo49g4StYK3WjcWv1cqJhLRZjPoOAjO8rcvLs_JIvZ8Nk6ZwRdGFXn-1njAXJ_Amk1PncnyoXCEfqvdhshEwYFIkWlTiM5m1NgKh4F4YfTNRWqOPDelWljBJMiV6MZQeUT2SPM36D74i8x3m4IjwWftG4Eb9-JYwJTDuoTge1HDkF2G9QVEq2R56kvvXwD2lfonSGoti67nIGB6oxfam518HMwZQRQkUNNnSNNQKbgT1kyluu8O9k_5P2425bUuxIi9neocZL9i4XSCTLuN9jQYiE_LvmmxQSXT0mhLc4f4bKJpfKU1ooQPB9wrE6PF-TxGmdx10ITPW6WTtOxiNqiArQIlHitWJSYkMUUxGfiCUCysxMxP9s6zWjCIK3L62_G_6u_PzDF-tZfTA-BZtaFYpdfKykxlSr4fcFi9JXXXs96v4mcTa28eWIa-aFB9IaJxZoRpnBKwDK-tnm86JBEV4Cwvm47WRMHq89GhaY9ySlsQ49ALr6gmRKPVGwFomNhYp4prupnfvH8mHtjs4eKRSjes62HP3nFKcPes7kMk6lT6SQIjrAcnudYnku1uzamY9VsMEWQ2glX5GThHVfUzvGDpabvCCI5ZDQC9X1tWgMxd8TVIKGFYga4PK2ecwCMMzuc-DTvUnvbfSIdtfLEXqH3GOV2LOTqn3T0ZL5FNnZX8Ub0jOF8wZswV33Dd3G4rCyQPc6sahLCwSLF0lvnziFuyi_VVGcQSDRcO3tdZsPnOMUrl9cuiNZP3s0gR0tLgBRT7dd5ztkMz-hHKaXNZtoukLUx06XNitk4Y_myk3_poVoZaXSazxaRbcouTt2TyUaZ9NBJfHi7VO66sRG8MgR8NGJtZo1ZCSj2HaCTC8DCMnC2WyVvYOZvjOTXBb5Fqlyo9OTrxitvXhOQ0pZk0lW0aqYR4RujSNJCTOn0U3Ypt12rC0wKxIw1YPeaOTVMCnXB5vNzCDBKM6pSPz9cNlPo0uTUnUeQOeT--2ur_qskhxpLE5NxfzwgC2_6z0sZze0WJgZWnDPQ3eEQqZlIbFF-9SOVfErdyJzmf14VzdDFKHqiMRob1c3JuzVMfWQcgZq0QyfmzAkZMmWp8qhmxnZDe_QXI48vNT-y8-nJPMPn6RVmdtgAOMCVCkHdeUyjB_rpQur27lgM=) and\nfollow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=lsW0_AKftEWyNLL92y2miRMJCHoqepSLU1zBZgOmO0HlKktnST76fluwEqhrswK-A45U1586VkAIeJq7sZ0UIi5HbyNOWX3Jg_IhuZ9IT6xlc-_Ih29uNgK_1yqZXeG24o-jGCJGOXbdTlYwuwgEdpkhmA6JWNR3bgB54h2MkVJpFkXBTCzoYFo1De_WbcZlqiSqyV_qzn3h2mG8ZnDui7ZNQwECV2sGIJBD2z1nAmsXHRVt70ITB7DA3iPZ3pzQzHUY83fbEoxJqkM4jJYBEgiPv5cJTekSQtnBghzKZVEwVAvemQNoOk4I3ZhGG7DChtZhcowjL2MUixRLzEqgIN6BbrPJ9KoTuQlM3yLP0WJyPdxGYR966SskX1UrJ0pjFhXGzr0p51gZZpJiWkC6siePxMbxil7WNdOVujB-Y0q4YLSxGS3oe_IZh2JO9T3cUkqTdZkvhHwLqs_NOy9e4nqvS10gP3TGK1bOfVValZP4y9Kc2qWqVLBdBe5OZo_0xJa4RaTqYFwIykMcs26yOconUfbcWuaUatcPlVwjlj7g-0ngABOmGCQnerd4BgFhAyTXSW0j2At5MpUWaHpk9LNKCF4t_u6-5qIkUCm1UZBHuXhxoCZ-bZo0nwNyVyhAO3rh8jCgJ7dUm7mkB-tkRM27K7Bwzx5Lefmw_5G2qibWCWUY_-advQUwPCrBT5jWuO9nP1gLjSgKl-Q00HZWrzqTgM-1TIxCstiE3Gv55bBya6pL5UaRsvp1pl-6NFb-CBFpvHUQikPMMFIiytRW6D0TBitbF2UTTIWCEZ3wNU13galNmrzBi3BEEZujZvxf3DnsKmDaCCxJc4E7jY6haS7RQp7UPDOyNqnrUyBpBO8GXvBrw8HZfPjxjspq4IOoJ-kLW5ZqEN_vRDjRwnpmc2oMsKlR4FlWUqhjRy_JIDoaKflqKcqQG7svGS6cNNzAYI_3Qxvox-465FP5-vvJKNcLgBaXingS1In3RVG3oVXrKOHenx4K9wHzPbKbnMir6U9hrKtv2ZQEy5qOVY26FydBL5CN1Td2AD5Iwu3XntdYBRauLzniPqR5x4qRTO5vlPRkXm_HxzXZbKxRPQd0gZIk2tN2KO6CFzqTokYIgWqezRdMqkfDzhon_9_bKwY8LOx7mZvt5A-h159TYdeO1_rHc5hO95UTNh5dHCb_T8q-s_nBQgIE326GjZda2WGZpwQ30n43JFhLPYLZRpMyOOIpXyuP3vor-hb4Hv4R1isMk7khy_cD7qferTBhMi2fQqQygpysPjwllFEDgobJgRBVz0ivwfiloQUxe9zLGzsRoqpj9skUNjYBsb6GgfBJw7oyHjvd4BpqPFH9XtYo8yxliSUL3GZ6rW8AphM70SFRUvGdjC1x55_5iHlUXWdhQYaUhC5RAv9lkBeAkCAh-jDtjwZrUbESH7bCKjlE2_vUUK4wrBlQwlgzFbalKaJdpupD1V-NTYptShWbVXb4fih2dQTx3bSKoJB_HNzXl3T0nYooF5I77I7eZGFv5BMe-unqNrF03o-iMn5gkoSDHu-_Tr9cdcF4y2zzKoj_zPuRiYvRbnnhv7pW-lyK4dAS1NVeOhGNkUFG9m3wGLDXQA==), X\n(https://www.globenewswire.com/Tracker?data=_K-eMubDB1oCjEgSPd7LQHUI6D0vCzDbolvbjvc-xW3S12QcNfgyTeJSUugjRiRqf68zkGUXyn7asyQJyzo-M_y0bXDF1Z9aMeBc8oL6UitinDDuNa37QCthr1AIHVW7Rh9o_907MwdYMOuW2WC8CU8_GFm1BnxFDP4EKID_-TsFqYnssi1N9nM6noJDtqkkRVv9MkMQmIcOgiplCJ2fJIlHsupJLzh20IHQ8pk1RR0w7ZWvlunkPn9yJIhR8Ic6JMbMyDkwqR_zZklWLmur2uqWal3jkIdLM-OIwJNPBN83ITfCLfOXLJPe2esNU-6QD5liqAqCiZmtuTsa4rsq9Zmu2XAzMLNLob3WMiaSYrtBum5hJZUPVjOVYefGNiTEoqsQZnhHvgLnPPMP9teNW_C_wMA9jJmJeovjdBaRqSO_RXSHRCj6QH-9xt7Xcpqnlq2ZEuLRS_hhR5amRPjksw1y72FB2Bnu273fRCTDyL5sPJdUWinkOo-AjJ1Lpb3-_-lMw14W4zA1HmpU6M1hFfrpgQ46qSf0thjtO9glQ7Wmwe7AHOTKsOjIkk4i7douVpoFzx0AuqRu3nPeBsta0sSWQS3GI4FbiNOEOAjaoFpq4YEAU3KllKbf61TNUZMwYepEa00vuGVKM6DKdoEMJldpcwRMYY5pgUE5kfFwnTtvFpfnPBu_Lo-5_vr2UWPYgIgrguQ9MDf2-DZTIAg984E8tOVrgPuJSPVoE87A4_MHlG46fHniTRFvNGwykJbWxShvcY6EjQDjcTjmQqLg6Cp2pNcDpwym1qfEhX3RUkvrI1zWoB2cy02QWtBV_-pemu_-RM-OetUHHvkiPexaLv6vNWL-LKmKbAcP0Eajly853hHSNRlGVfJ7UDMlp5DZLfjFOkRGdKyr-SWgZptqBP02Ebl0dytRWnKPi3ytyazJe7CQYCt9lXUYpfrTS0SI_P8fq2f13VZ-fF8fmTzUdYg_BVtE9PxNBbawOKUHl6buFpmqeKQlZhi2u0YUNjg65dVW6TQoPAmkKIwoYoHxrPbiO9o3WZ2LO-QBPt-P9mZwmc6VCfKokKXy7LwOQKxcvSKN0yjYehzZ8O8M14DGtBXiGoP73Y6yj6ErV6fRHtFcW6gHuBoyypVqgH7tma_roLRb8zNO_W2vdzs64npMTjrPjXPHsWaGT2560-DR7bFlxOe99OTvvXIdgVMNYwz4zHCbx8OZ6vqypXe4bPpGrg-iq25q0bfurcvI1CAUKcOjW4p0EZgq6Uw9XTVlT0EUZhDDRrAv8cqxGywRhjzwD2VT6B_6OVHfSQqPI9H6ytJ2BBp9a_csVbYfMQSfq-yQdEOeINWwV2343kVzNtTl7A==), Instagram\n(https://www.globenewswire.com/Tracker?data=hNByROEpaYe5XHgVu3oyqge1ZOLR-EJOMR6CvzbSYaWf3M7jv3AKYiQIETJbcPWtdQrqICClJVvKkAChMVpEYuNKHWx-rQDD1oTwEU6ZaSptdGLS8u7NWHV7dCSmjiWt6j4anbjdSgyybJ7ZOR-C7omVH1704J-LtTbmRRAWtgvY1hCGCAf90KPDapSRucICXJxKcfPrpozcHDtO4iXk2IIPKIGhDuX_Aj6svU17YdAketna2MbtlzUX-rtJ4KPTwkR1IX6w9sP-f1o3HM2urMSKKbBdk08gaqshgnCtp2-LiG8buin3RUqUqtYrPxPS8gwoOdTK5JpxsrpeB8J4T_Y08HNJMU7916SaI_fUoA5jqMOdUiirqZJpympN6WDLhgq0m9Mr9-rBOx2CyZWG6oP63ljAa6qy49jxPMlZNSbmF36C1ONNPQvmi_iYT4X8SCMXdzAvrZBi-vr3kuSBp4HBUnvRGx9anoRE5XirzgJvvvhvknLnF9eljcNV8ol0Cr9sFYEy1dq7aduFxdArjLiJTiNpBwoZwc-8hdDovNESNIdJXPm3_AIazCEKntYQq1CT5iBsKKfH4fwTRMU15I644f1EwH4rY14XxwJbUdyaS9jP-rcjrLMdqxBh-bzmgjXZ37cZ2JIEt8NXmimAiFbzHzDzvojBXkCLvSCgsKrfUsnM4nbyS9lUCd3XyHiwp6ffDFKAMQxHh6QVOqi_fvh5M882yPwSaMaF0VRuFlK-HtyEkuQI1ePxb74PgfGDHCa3NM4cnK2BYYed19mehZuwdsj8hp4CMXO5GOOPA2qmjOx9HmtIoQWzYUEF0Gm3p132e-YhPTIoBfCdTYNN7Mckb3lqBTo_hTCBzmxV1XlANBKpo4Y581Ujj9i7ZaNuBdpv-2lxL9tN9WmcnVHKxA8qEBPEsDr-cizP2EYd5NxuTC3V88M4kiKkHVECzILadLCz3at0HHJ_RK0RrQIgPuXwEGzZCa_hcGFXDCI-NvZZ3tnp9YyCLbmvJsFEHSvSJPN4RdmMQwVPX-7QjMWQIr7b5lQVchWCM1YoypMH7ieuVHGeaqYJELv8VicfDR5F_RDVzrYLNXArN3ZcR3G88ot9obdRBmeNrIC_pQZjrWrLiM2mfvdm5-zZ8Lq3GF7AzwTvtPB67hox1gZuHspkA7pfwJKXBQLGTe9ZLYcjJsVxnMcIuqnXBT7FTm2GXYC3pLL7vy4xYGEQsixSr-2vlJIEZEJBuOQ1tN_lq5mpuGxn48lscpuB4ayLb6oV0E_JG-gEAB6UOH7kIY7DE5B5L7Tdn3WSd7FxNOH1lUURJMavRNxUN83HI9c6fe6Oi2LCy43dw0uz3mdOzH512pAp4LQyg0pEUgab-AyTckqIYTSzIwoCaZpF_eqzs-iTT2t4bENiu-BBFyjUOTtlSAk5bT74u75nGbVeDReNegqHYANal6ulei8TpOHXVb3FGJuH9QWQMbbDfie8R6S6bOzhPGGjbbEjzuTgV4bycHzmM6KCRsvJtWh5qhvBfH-THHfuX52DTBpVWbBJvabyVCytLPBPy7q5tTQr2I0wdGaMJxvotIN3OND0BbbhZvVtNiab), Apple\nPodcasts\n(https://www.globenewswire.com/Tracker?data=Os9oBB5K8FeEVVDA3K-LaNh09L9w-tEEUKbhThObwaULX6Z4avIbFV-efVUii-DZmF2jynqb8xnUYVHGcUTYzbk5AtFqAZOhKP9XrJBez3p53doiGKnFukqIBI79H4Hmjxw-DXrwCT9LNKYEvHwIx-6rXOVaxC6KtB5EV3hgkxF4mk1uGOXy9QteHJUnJ3JSOGuDkV1-t0twWR_vwdBWttkRGO6o7SGQg2q6atLWni3OhG4aBs5AKMeHfh98CtjcR7bGaTdAO486Wuy5TwitUQ3I5Qc4Ej7Ky1pU2rtf5PmsK3vRXX5IE9BTzms_PrhlJ1-eB-WFa3vaNCZ4luSuMG8vx8oOIyIR5LKXxs-TgPxJbqCiln9CJg-eKTOmdx8oaPpapXVpw4wQIvPqxpqb-ieypM8ziz6MQNAUAn1Jrv3L6ixyV3ijH42ciXu03o3dwrbKZvG59TFUqtRhgxO4Fl8cY9XE3s2EfD3xDcbpG_XE8XXsQXSyy-FGe_lyfiJ3I6PkkDlw49mzYpnr1lyBNlD6ssvjgbcDwbXXCLM1gW5Im3h2kpoujzhecLTqo4GTw0r5q5ibJqwZQWuu2mJitpJMEG0IxypPyH7qGgdaCY_jQes1GPwSWWzZsK_-Y7yUvoFrxjpBTMe7pRmOJurDrEcnpRo0AsGY1f3eL_I_SyzilXjabJ3gQSt7zIaltvTNH15WuH68kZACmNB9Da-74gPqqJRAgkJF0gh68_Kik08QYYTKHBuYCs0H1BlW28Yy7r1tEdkvaFqIDXFSY3bn193TNKp8HSEJh5mGPlSWUnAR3wE8w86JWsXRzw2cXvsx4A5WmX6F4vcd-PoabIL5xKydZPSeeP4jKzBQbhdj39MwZpnktSrmClGLd6KdRU2Xfu0l5epLjt_Kjl6q_wtrMQ4WIpr2IKf4NSVcDR3u3y8KM229FnsnB0SLEwaNTLgNvRxAKBHHCaT4IO1Kz05PrTLSYi98QjgbSc4biFj95sw7dPLcfFsmNOq8G1mhQEpSDzLTfccD72XxW4rfkaeWMtGD101_Fl-sePzGYr4KMfShLjWnVS56MRJuWGLponO6HskD226sze9G31XvH5h5Cv4QzsmEgmT_EM09Mxzwrep4RTthLqhkQeyrkHXo_scAsRDiGxlXuLS99MHvgTzV-G55iDUEF7rFeymoNGhuL4OAynxKLrI9T5kxxhbdXAdCkDIeLYW_Ot48A6IlE8J7Y2S4oHxbbFeYNs4i-26VV_GN53k33PtKryUDlibNBhiS5COogVfclwBQQ7dV4RRFOmIIfWm7vAU_h2Wq4lankAswv7vrWJs1AR48y8Qw_iRwB2dZ_s4fnME58119KwrNcoLiFL5ZFnRg-oeAYxhLq--GCEuoFfggb1Cd1JBxlV3RnnqPxXFLlgohJKcM5DQUb1rRLDBUyU-PCxnUwYnHhgX8K72FwDAuTpjukPqfE118n4KlPLkAXRGOyyBFY6rTyubRMdUlH-p9u99c_27er3BAQ_W_TSNW64uxr2WKPkjpe5lfKCL7Q3X40u0un_Vf9qNlr288pYv1VFb9b4jnxVphguzaDvWIvU-HwQb9hEHTZHO78BMFRjuIdnhBSQdhPtjedgA0rIb0TjQHBu6MgiBEoPCPtLeH98woBKKLIrcdtgQ-5yz1-ObNEO5GfrDpr84v-BU-wgScg6pkVEMFkaltw_1UB8QK_yUKcbdK05-yjsnaew9YesDvPOQr9d7QOzd8GkINposftp2T44fyRE4JwT7H4lwYvfiUcQy8mftq7X9m2Xv9oVVTQnE_IHWSg7ZJ5EewHMhm_IjHfSjwP6c=) and Spotify\n(https://www.globenewswire.com/Tracker?data=TJJgICgwctmMYocEqleIdH344z0D0EMKi0HhXJDq-SE6O9rjLqXHYm_MZJiZQjgZ4gEMNNo1vRXSBtR62J-huDW2LVJ1afNetDWnKrzYbyNz6R_LbDbWwVSgt0-UNoB7tTG-MtKuXjIIgz9HrLtDo8dehmPqo--WZJ2cAPJN_fzgdheefg0HHZTvGQHRY3LV-Hq3df3fgVpCEcXYORH-xFZOIw6mtliEhQN1RYfbE2UgeCeMeUndX9fvfbHlOgl9_BcpREeuppZ13_O0yinfUb4gy9WXDAOCNr-ctZptrT2EE0UoeskJCOnIMpmr6jZdPA-PEhIorLRye_sE8bqEARpFofPpDh42CFZmxNK81nIFI0w2GcDcpFW4KtWJC_a37p7BYDqsu8Vt0hXPzWwbcQ3mwg_hJz2J70MOFPK6ZyRpXVQBfcCd3Cz3vShSKXXoiWzFyJNDSSSSR-axsq-AN0NxbtiT4FDeg-MQO-xUZbcG4jAkimfAZwvXN8saVJ1DWJQjLSg8DOA8K6VnTd-bq4vcm6m_gh-0HQ8XxbrVdax-dbc478SC0WdQ1zl13SVEb_aHKkYXz5SqjKt_CX7VkjLxNQloOgK7FIVKA5OPEFFbN1NWs8s4qGK3FmPvVlSkIiAsOLd1KuU_yc8x30_rogCsArGXJ5Lt_1SeyErDJuxJwcp14URzARWtpWSI81sw-BYbfACrTyvmpnrGrJ82k9VQTb4NgwyLIRVSPSY8cXAYxIWitBuC1eRQW0Y0YNSGhxnBpmB9mfCUqpm9X2Sh1wrYmYXLxMqCHsbXMmj9e9MBeikekfSlZUO8Xsg9GNw5sb1FPa2YP182_ZlFQ-DeL14QKw3KfsWsvQVfwEGJMUvCoeql9lVby0CIU1-IFhXAxU77TwnnuF_rp2K7iiUueRv0IPKwGOQfeLaB32ksyZym_b5mv4w2iTSZwBTKzyl0Jrn33tagoV20-VdjvRIgAAdiOt5FUbPqz_l1qLGqpIwdQg1lpC_5zWRGHnTs9cAEhpSBt0jdlh5ZRLx1RfHUwMn4gdR66PlCK9oqXfFaw8xugPdlAw5G8HE4AbOXBREsjZ7ojHdS7a1SULPYFT5sHu5lBnt9sFqiYeD82XoxWSD3198Xlg7lJ5_2k8isg_bkt7Bhj8Iz6430OySR7Cm9kLvOAE8yNg7sGc_bx4BDUnWaCqPyQphbk0esB1_fH1LBfGjUxj51ilqcHACEKpQaTT159lLDGrUW5gTTC_J892sYzPJQwPhtvZd4Tjq4S8sQFTJ7t2Nr3LReZWaTbFr3wJOBYI7sOqpg8jlr52PjeceBmrTYCGFsLXFxe_XWZmlrkOsRQqdJXAEFO7HZO3hTz8wA_qA9fLAhLMNmT-NsAxxOqgKtMP63oWQ88lDdvMnULdJbCNbxBsjfsLlHdDsTGFPsKtRlSd0r6jIV0FIl1fXrCVjC6wslXFe5r-gE_nII-keKmNV-emmt9UXZWpVO3YWsPhU4-FXPzTz6011sSYXvrDIDaHmalZac2KY6HUfYGweIMMfGWpJI3UtLY1wtTzdzYtoRH2AaLhHS_1wOk5EVF3-V8oIW5Z006rNUxhveWUhDmnwMkWbghuWBygYAvg==). \n\nSafe Harbor Statement \nThis press release includes forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. All statements, other\nthan statements of historical fact, are forward-looking statements. We\ngenerally identify forward-looking statements by using words like\n“anticipate,” “believe,” “continue,” “could,” “estimate,”\n“expect,” “forecast,” “goal,” “intend,” “may,” “plan,”\n“should,” “will,” “would,” and similar expressions or variations\nthereof, or the negative thereof, but these terms are not the exclusive means\nof identifying such statements. Forward-looking statements are based on our\ncurrent intentions, beliefs, and expectations regarding future events based on\ninformation that is currently available. We cannot guarantee that any\nforward-looking statement will be accurate. Readers should realize that if\nunderlying assumptions prove inaccurate or if known or unknown risks or\nuncertainties materialize, actual results could differ materially from our\nexpectations. Readers are, therefore, cautioned not to place undue reliance on\nany forward-looking statement. Any forward-looking statement speaks only as of\nthe date of this press release, and, except as required by law, we do not\nundertake to update any forward-looking statement to reflect new information,\nevents, or circumstances. Readers should consider this cautionary statement,\nas well as the risk factors identified in our periodic reports filed with\nthe U.S. Securities and Exchange Commission, when evaluating our\nforward-looking statements. \n\nInvestor Contact:\nRichard S. Lindahl\nExecutive Vice President, CFO\nlindahlr@ebsi.com\n\nMedia Contact:\nAssal Hellmer\nVice President, Communications\nmediarelations@ebsi.com\n\n(1)Smallpox as a Weapon for Bioterrorism\n(https://www.globenewswire.com/Tracker?data=dDCF-ROtUxOmbhVGbrmLtYgEWpa80oLh2U7NRU_0oac09HiTZIU77cgPWmL4aN0VzV2xIEJ_2WulDtNtJ7isftLWLMpp71Co-2aO3X2VU2uaEpaURgoPm524AaaMlBdmI2NQqARRBmx1obgmGfM4_9naTGRp7WJexAwh728of1o=)\n\n(2 )Mpox 2022 to 2025 Update: A Comprehensive Review on Its Complications,\nTransmission, Diagnosis, and Treatment\n(https://www.globenewswire.com/Tracker?data=dMxv5MYUNhZwivavc3X1Igaiyhej_uIXv_wOh6r90KGYyypWk_85q6JORKrrOErlYcMMZLEWSO7nmn_0nvsgyR08Tfr5mgO1BVIkRGbAFCKLTqX0edQfsBWSSsxd5jIaKziyOfosvzqAmmXp_cwqDYl0FU5SrKUnBp2lWUCgtlJORo588itcqdda5dqmBiicQjkX5ebqaMAmXjjz5ZtWIGVAglUZJYK_HWPIONoh1HbbTpx1485fuL9ZwUF3Q4wK)\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/56a9097d-af91-4bcf-8c42-5905e1614ef1)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX24Hxnf","title":"Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]","author":"Globe Newswire","ticker":"EBS","created":"2026-05-18T12:59:00.141Z","tickers":["EBS"],"exchange":"NYSE","article_body":"GAITHERSBURG, Md., May 18, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions\n(NYSE:EBS), a global biodefense company, today announced that the Saudi Food\nand Drug Authority (SFDA) has approved the registration of ACAM2000®\n[Smallpox and Mpox  (Vaccinia) Vaccine, Live], for the prevention of smallpox\nand mpox disease in individuals determined to be at high risk for smallpox or\nmpox infection. This follows Emergent’s recent announcement\n(https://www.globenewswire.com/Tracker?data=Ea8TQEEr3uSK98w44E2YjD_jnv2GcxLHG-QPV9jwPHROX2pCu0ImUT8SFY8OX9LGx5F24dcSRrCybRo4W9HKGqait_16aRXZg3zuEfVizOsBBLFsM_frOjrpgVF6RC2XtB2Hht1zpnhfuyz6s9d02pRSHdUfoO3IpFHG-LHPVAWSCHsN19rzqshbbbn-3PU3W6Qvv4zZ0-BJXxn0EWn0rR89X9oe84-k5q-0hTy8p3U=)\nthat Singapore’s Health Sciences Authority (HSA) has approved an expanded\nindication for ACAM2000(® )[Smallpox and Mpox (Vaccinia) Vaccine, Live] to\ninclude prevention of mpox disease in adults determined to be at high risk for\nmpox infection.\n\n“We are pleased to receive this approval for ACAM2000(®) from SFDA for\nimmunization against smallpox and mpox in high-risk individuals,” said Simon\nLowry, chief medical officer of Emergent. “ACAM2000(®) is the first\nEmergent product to be licensed by the SFDA and demonstrates the company’s\nintent to collaborate with governments in the Gulf region and around the world\nas awareness and adoption of biodefense preparedness strategies continues to\nincrease around the world.”\n\nSmallpox is considered a credible bioterror threat by experts, and its\nmortality makes it a potential high-impact threat with health, economic and\nnational security implications.(1 )Mpox virus is part of the same family of\nviruses as variola virus, the virus that causes smallpox. Since the start of\nthe global outbreak of mpox in 2022, there have been more than 137,000\nconfirmed cases and more than 300 deaths reported globally.(2)\n\nEmergent specializes in developing, manufacturing and delivering medical\ncountermeasures to governments around the world for national security and\nhealth preparedness. These products support how governments respond to\nemergencies and help protect the public from potential threats like smallpox,\nmpox, anthrax and botulism.\n\nIndication and Select Important Safety Information for ACAM2000(®) [Smallpox\nand Mpox (Vaccinia) Vaccine, Live]\nIndication\nACAM2000(®) is indicated for active immunization for the prevention of\nsmallpox and mpox disease in individuals determined to be at high risk for\nsmallpox or mpox infection.\n\nImportant Safety Information \nWarning: Serious Complications \nMyocarditis and pericarditis (suspect cases observed at a rate of 5.7 per 1000\nprimary vaccinees (95% CI: 1.9-13.3)), encephalitis, encephalomyelitis,\nencephalopathy, progressive vaccinia, generalized vaccinia, severe vaccinial\nskin infections, erythema multiforme major (including STEVENS-JOHNSON\nSYNDROME), eczema vaccinatum resulting in permanent sequelae or death,\naccidental eye infection (ocular vaccinia) which can cause ocular\ncomplications that may lead to blindness, and fetal death, have occurred\nfollowing either primary vaccination or revaccination with ACAM2000(®) or\nother live vaccinia virus vaccines that were used historically.\n\nContraindications\nDo not administer ACAM2000(®) to individuals with severe immunodeficiency.\nThese individuals may include persons who are undergoing bone marrow\ntransplantation or persons with primary or acquired immunodeficiency states\nwho require isolation.\n\nWarnings and Precautions\nSerious complications that may follow either primary or revaccination with\nACAM2000(®) include myocarditis and/or pericarditis, ischemic heart disease\nand non-ischemic dilated cardiomyopathy, encephalitis, encephalomyelitis,\nencephalopathy, progressive vaccinia (vaccinia necrosum), generalized\nvaccinia, severe vaccinial skin infections, erythema multiforme major\n(including Stevens-Johnson syndrome), eczema vaccinatum, fetal at\n1-877-246-8472 (U.S.), 1-800-768-2304 (Canada), or\nmedicalinformation@ebsi.com; or VAERS at 1-800-822-7967 or\nhttps://vaers.hhs.gov. Please see the full Prescribing Information\n(https://www.globenewswire.com/Tracker?data=HTifwnnS7SElnnsT0I5k7GtroTSSlB9fCV32WQZldwhYg8YXM-_mTqUgQ9WobUHzQ2h8M_7EefK08wDsRUfR7Np3bkVN74K4Rb9Rvl5ap-foOSaZXyyMc68bxEVDhRWchN5UdV0KpTmHPT1TsGghzMEMSiizUNSrSXgQOsKErk1VMqUzlRo7VybELanCbXWMUaXe1BDWQKq7VGscHYVZdy2Rkc6Cq1c121a7UjpX9zqhbBwvmdXOhs51prMgXwh0)\nfor ACAM2000(®) for complete Boxed Warning and safety information.\n\nAbout Emergent BioSolutions\nAt Emergent, our mission is to protect and save lives. For over 25\nyears, we’ve been at work preparing those entrusted with protecting public\nhealth. We deliver protective and life-saving solutions for health threats\nlike smallpox, mpox, botulism, Ebola, anthrax and opioid overdose\nemergencies. To learn more about how we help prepare communities around the\nworld for today’s health challenges and tomorrow’s threats, visit\nour website\n(https://www.globenewswire.com/Tracker?data=UDYUkxCarH-pcCWkjxjsT-7j6PYLxwcQcEVGLeGWrnEE14guzpUQ_PQbuEx55aCTwDSlgGyMflxzVk08jYPZdqRZalvm7emvYrta8uALHJzl8uBjUTqfC5Cwmu_xtGEK5tjWgMrlIenQyv7wOsdwOe2eHHP471AA8pfh7xZaVxHV8ipaO4Vx-CWmziDYqNOXR6PCrYvmIpwg3YongOmARHxXkIhC7PvduAqF14WLQamupiqDdwfHk5Dh90WpcVvAJ9wZnYN_yogp-dDkSjR4qSFhIO5ToWwmTnrKkcz3Cy3Iu8u0EQFkPjKWxUUa1d97Fld-TdAHM_K9VnB9riSGUSZSxlVaSwo49g4StYK3WjcWv1cqJhLRZjPoOAjO8rcvLs_JIvZ8Nk6ZwRdGFXn-1njAXJ_Amk1PncnyoXCEfqvdhshEwYFIkWlTiM5m1NgKh4F4YfTNRWqOPDelWljBJMiV6MZQeUT2SPM36D74i8x3m4IjwWftG4Eb9-JYwJTDuoTge1HDkF2G9QVEq2R56kvvXwD2lfonSGoti67nIGB6oxfam518HMwZQRQkUNNnSNNQKbgT1kyluu8O9k_5P2425bUuxIi9neocZL9i4XSCTLuN9jQYiE_LvmmxQSXT0mhLc4f4bKJpfKU1ooQPB9wrE6PF-TxGmdx10ITPW6WTtOxiNqiArQIlHitWJSYkMUUxGfiCUCysxMxP9s6zWjCIK3L62_G_6u_PzDF-tZfTA-BZtaFYpdfKykxlSr4fcFi9JXXXs96v4mcTa28eWIa-aFB9IaJxZoRpnBKwDK-tnm86JBEV4Cwvm47WRMHq89GhaY9ySlsQ49ALr6gmRKPVGwFomNhYp4prupnfvH8mHtjs4eKRSjes62HP3nFKcPes7kMk6lT6SQIjrAcnudYnku1uzamY9VsMEWQ2glX5GThHVfUzvGDpabvCCI5ZDQC9X1tWgMxd8TVIKGFYga4PK2ecwCMMzuc-DTvUnvbfSIdtfLEXqH3GOV2LOTqn3T0ZL5FNnZX8Ub0jOF8wZswV33Dd3G4rCyQPc6sahLCwSLF0lvnziFuyi_VVGcQSDRcO3tdZsPnOMUrl9cuiNZP3s0gR0tLgBRT7dd5ztkMz-hHKaXNZtoukLUx06XNitk4Y_myk3_poVoZaXSazxaRbcouTt2TyUaZ9NBJfHi7VO66sRG8MgR8NGJtZo1ZCSj2HaCTC8DCMnC2WyVvYOZvjOTXBb5Fqlyo9OTrxitvXhOQ0pZk0lW0aqYR4RujSNJCTOn0U3Ypt12rC0wKxIw1YPeaOTVMCnXB5vNzCDBKM6pSPz9cNlPo0uTUnUeQOeT--2ur_qskhxpLE5NxfzwgC2_6z0sZze0WJgZWnDPQ3eEQqZlIbFF-9SOVfErdyJzmf14VzdDFKHqiMRob1c3JuzVMfWQcgZq0QyfmzAkZMmWp8qhmxnZDe_QXI48vNT-y8-nJPMPn6RVmdtgAOMCVCkHdeUyjB_rpQur27lgM=) and\nfollow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=lsW0_AKftEWyNLL92y2miRMJCHoqepSLU1zBZgOmO0HlKktnST76fluwEqhrswK-A45U1586VkAIeJq7sZ0UIi5HbyNOWX3Jg_IhuZ9IT6xlc-_Ih29uNgK_1yqZXeG24o-jGCJGOXbdTlYwuwgEdpkhmA6JWNR3bgB54h2MkVJpFkXBTCzoYFo1De_WbcZlqiSqyV_qzn3h2mG8ZnDui7ZNQwECV2sGIJBD2z1nAmsXHRVt70ITB7DA3iPZ3pzQzHUY83fbEoxJqkM4jJYBEgiPv5cJTekSQtnBghzKZVEwVAvemQNoOk4I3ZhGG7DChtZhcowjL2MUixRLzEqgIN6BbrPJ9KoTuQlM3yLP0WJyPdxGYR966SskX1UrJ0pjFhXGzr0p51gZZpJiWkC6siePxMbxil7WNdOVujB-Y0q4YLSxGS3oe_IZh2JO9T3cUkqTdZkvhHwLqs_NOy9e4nqvS10gP3TGK1bOfVValZP4y9Kc2qWqVLBdBe5OZo_0xJa4RaTqYFwIykMcs26yOconUfbcWuaUatcPlVwjlj7g-0ngABOmGCQnerd4BgFhAyTXSW0j2At5MpUWaHpk9LNKCF4t_u6-5qIkUCm1UZBHuXhxoCZ-bZo0nwNyVyhAO3rh8jCgJ7dUm7mkB-tkRM27K7Bwzx5Lefmw_5G2qibWCWUY_-advQUwPCrBT5jWuO9nP1gLjSgKl-Q00HZWrzqTgM-1TIxCstiE3Gv55bBya6pL5UaRsvp1pl-6NFb-CBFpvHUQikPMMFIiytRW6D0TBitbF2UTTIWCEZ3wNU13galNmrzBi3BEEZujZvxf3DnsKmDaCCxJc4E7jY6haS7RQp7UPDOyNqnrUyBpBO8GXvBrw8HZfPjxjspq4IOoJ-kLW5ZqEN_vRDjRwnpmc2oMsKlR4FlWUqhjRy_JIDoaKflqKcqQG7svGS6cNNzAYI_3Qxvox-465FP5-vvJKNcLgBaXingS1In3RVG3oVXrKOHenx4K9wHzPbKbnMir6U9hrKtv2ZQEy5qOVY26FydBL5CN1Td2AD5Iwu3XntdYBRauLzniPqR5x4qRTO5vlPRkXm_HxzXZbKxRPQd0gZIk2tN2KO6CFzqTokYIgWqezRdMqkfDzhon_9_bKwY8LOx7mZvt5A-h159TYdeO1_rHc5hO95UTNh5dHCb_T8q-s_nBQgIE326GjZda2WGZpwQ30n43JFhLPYLZRpMyOOIpXyuP3vor-hb4Hv4R1isMk7khy_cD7qferTBhMi2fQqQygpysPjwllFEDgobJgRBVz0ivwfiloQUxe9zLGzsRoqpj9skUNjYBsb6GgfBJw7oyHjvd4BpqPFH9XtYo8yxliSUL3GZ6rW8AphM70SFRUvGdjC1x55_5iHlUXWdhQYaUhC5RAv9lkBeAkCAh-jDtjwZrUbESH7bCKjlE2_vUUK4wrBlQwlgzFbalKaJdpupD1V-NTYptShWbVXb4fih2dQTx3bSKoJB_HNzXl3T0nYooF5I77I7eZGFv5BMe-unqNrF03o-iMn5gkoSDHu-_Tr9cdcF4y2zzKoj_zPuRiYvRbnnhv7pW-lyK4dAS1NVeOhGNkUFG9m3wGLDXQA==), X\n(https://www.globenewswire.com/Tracker?data=_K-eMubDB1oCjEgSPd7LQHUI6D0vCzDbolvbjvc-xW3S12QcNfgyTeJSUugjRiRqf68zkGUXyn7asyQJyzo-M_y0bXDF1Z9aMeBc8oL6UitinDDuNa37QCthr1AIHVW7Rh9o_907MwdYMOuW2WC8CU8_GFm1BnxFDP4EKID_-TsFqYnssi1N9nM6noJDtqkkRVv9MkMQmIcOgiplCJ2fJIlHsupJLzh20IHQ8pk1RR0w7ZWvlunkPn9yJIhR8Ic6JMbMyDkwqR_zZklWLmur2uqWal3jkIdLM-OIwJNPBN83ITfCLfOXLJPe2esNU-6QD5liqAqCiZmtuTsa4rsq9Zmu2XAzMLNLob3WMiaSYrtBum5hJZUPVjOVYefGNiTEoqsQZnhHvgLnPPMP9teNW_C_wMA9jJmJeovjdBaRqSO_RXSHRCj6QH-9xt7Xcpqnlq2ZEuLRS_hhR5amRPjksw1y72FB2Bnu273fRCTDyL5sPJdUWinkOo-AjJ1Lpb3-_-lMw14W4zA1HmpU6M1hFfrpgQ46qSf0thjtO9glQ7Wmwe7AHOTKsOjIkk4i7douVpoFzx0AuqRu3nPeBsta0sSWQS3GI4FbiNOEOAjaoFpq4YEAU3KllKbf61TNUZMwYepEa00vuGVKM6DKdoEMJldpcwRMYY5pgUE5kfFwnTtvFpfnPBu_Lo-5_vr2UWPYgIgrguQ9MDf2-DZTIAg984E8tOVrgPuJSPVoE87A4_MHlG46fHniTRFvNGwykJbWxShvcY6EjQDjcTjmQqLg6Cp2pNcDpwym1qfEhX3RUkvrI1zWoB2cy02QWtBV_-pemu_-RM-OetUHHvkiPexaLv6vNWL-LKmKbAcP0Eajly853hHSNRlGVfJ7UDMlp5DZLfjFOkRGdKyr-SWgZptqBP02Ebl0dytRWnKPi3ytyazJe7CQYCt9lXUYpfrTS0SI_P8fq2f13VZ-fF8fmTzUdYg_BVtE9PxNBbawOKUHl6buFpmqeKQlZhi2u0YUNjg65dVW6TQoPAmkKIwoYoHxrPbiO9o3WZ2LO-QBPt-P9mZwmc6VCfKokKXy7LwOQKxcvSKN0yjYehzZ8O8M14DGtBXiGoP73Y6yj6ErV6fRHtFcW6gHuBoyypVqgH7tma_roLRb8zNO_W2vdzs64npMTjrPjXPHsWaGT2560-DR7bFlxOe99OTvvXIdgVMNYwz4zHCbx8OZ6vqypXe4bPpGrg-iq25q0bfurcvI1CAUKcOjW4p0EZgq6Uw9XTVlT0EUZhDDRrAv8cqxGywRhjzwD2VT6B_6OVHfSQqPI9H6ytJ2BBp9a_csVbYfMQSfq-yQdEOeINWwV2343kVzNtTl7A==), Instagram\n(https://www.globenewswire.com/Tracker?data=hNByROEpaYe5XHgVu3oyqge1ZOLR-EJOMR6CvzbSYaWf3M7jv3AKYiQIETJbcPWtdQrqICClJVvKkAChMVpEYuNKHWx-rQDD1oTwEU6ZaSptdGLS8u7NWHV7dCSmjiWt6j4anbjdSgyybJ7ZOR-C7omVH1704J-LtTbmRRAWtgvY1hCGCAf90KPDapSRucICXJxKcfPrpozcHDtO4iXk2IIPKIGhDuX_Aj6svU17YdAketna2MbtlzUX-rtJ4KPTwkR1IX6w9sP-f1o3HM2urMSKKbBdk08gaqshgnCtp2-LiG8buin3RUqUqtYrPxPS8gwoOdTK5JpxsrpeB8J4T_Y08HNJMU7916SaI_fUoA5jqMOdUiirqZJpympN6WDLhgq0m9Mr9-rBOx2CyZWG6oP63ljAa6qy49jxPMlZNSbmF36C1ONNPQvmi_iYT4X8SCMXdzAvrZBi-vr3kuSBp4HBUnvRGx9anoRE5XirzgJvvvhvknLnF9eljcNV8ol0Cr9sFYEy1dq7aduFxdArjLiJTiNpBwoZwc-8hdDovNESNIdJXPm3_AIazCEKntYQq1CT5iBsKKfH4fwTRMU15I644f1EwH4rY14XxwJbUdyaS9jP-rcjrLMdqxBh-bzmgjXZ37cZ2JIEt8NXmimAiFbzHzDzvojBXkCLvSCgsKrfUsnM4nbyS9lUCd3XyHiwp6ffDFKAMQxHh6QVOqi_fvh5M882yPwSaMaF0VRuFlK-HtyEkuQI1ePxb74PgfGDHCa3NM4cnK2BYYed19mehZuwdsj8hp4CMXO5GOOPA2qmjOx9HmtIoQWzYUEF0Gm3p132e-YhPTIoBfCdTYNN7Mckb3lqBTo_hTCBzmxV1XlANBKpo4Y581Ujj9i7ZaNuBdpv-2lxL9tN9WmcnVHKxA8qEBPEsDr-cizP2EYd5NxuTC3V88M4kiKkHVECzILadLCz3at0HHJ_RK0RrQIgPuXwEGzZCa_hcGFXDCI-NvZZ3tnp9YyCLbmvJsFEHSvSJPN4RdmMQwVPX-7QjMWQIr7b5lQVchWCM1YoypMH7ieuVHGeaqYJELv8VicfDR5F_RDVzrYLNXArN3ZcR3G88ot9obdRBmeNrIC_pQZjrWrLiM2mfvdm5-zZ8Lq3GF7AzwTvtPB67hox1gZuHspkA7pfwJKXBQLGTe9ZLYcjJsVxnMcIuqnXBT7FTm2GXYC3pLL7vy4xYGEQsixSr-2vlJIEZEJBuOQ1tN_lq5mpuGxn48lscpuB4ayLb6oV0E_JG-gEAB6UOH7kIY7DE5B5L7Tdn3WSd7FxNOH1lUURJMavRNxUN83HI9c6fe6Oi2LCy43dw0uz3mdOzH512pAp4LQyg0pEUgab-AyTckqIYTSzIwoCaZpF_eqzs-iTT2t4bENiu-BBFyjUOTtlSAk5bT74u75nGbVeDReNegqHYANal6ulei8TpOHXVb3FGJuH9QWQMbbDfie8R6S6bOzhPGGjbbEjzuTgV4bycHzmM6KCRsvJtWh5qhvBfH-THHfuX52DTBpVWbBJvabyVCytLPBPy7q5tTQr2I0wdGaMJxvotIN3OND0BbbhZvVtNiab), Apple\nPodcasts\n(https://www.globenewswire.com/Tracker?data=Os9oBB5K8FeEVVDA3K-LaNh09L9w-tEEUKbhThObwaULX6Z4avIbFV-efVUii-DZmF2jynqb8xnUYVHGcUTYzbk5AtFqAZOhKP9XrJBez3p53doiGKnFukqIBI79H4Hmjxw-DXrwCT9LNKYEvHwIx-6rXOVaxC6KtB5EV3hgkxF4mk1uGOXy9QteHJUnJ3JSOGuDkV1-t0twWR_vwdBWttkRGO6o7SGQg2q6atLWni3OhG4aBs5AKMeHfh98CtjcR7bGaTdAO486Wuy5TwitUQ3I5Qc4Ej7Ky1pU2rtf5PmsK3vRXX5IE9BTzms_PrhlJ1-eB-WFa3vaNCZ4luSuMG8vx8oOIyIR5LKXxs-TgPxJbqCiln9CJg-eKTOmdx8oaPpapXVpw4wQIvPqxpqb-ieypM8ziz6MQNAUAn1Jrv3L6ixyV3ijH42ciXu03o3dwrbKZvG59TFUqtRhgxO4Fl8cY9XE3s2EfD3xDcbpG_XE8XXsQXSyy-FGe_lyfiJ3I6PkkDlw49mzYpnr1lyBNlD6ssvjgbcDwbXXCLM1gW5Im3h2kpoujzhecLTqo4GTw0r5q5ibJqwZQWuu2mJitpJMEG0IxypPyH7qGgdaCY_jQes1GPwSWWzZsK_-Y7yUvoFrxjpBTMe7pRmOJurDrEcnpRo0AsGY1f3eL_I_SyzilXjabJ3gQSt7zIaltvTNH15WuH68kZACmNB9Da-74gPqqJRAgkJF0gh68_Kik08QYYTKHBuYCs0H1BlW28Yy7r1tEdkvaFqIDXFSY3bn193TNKp8HSEJh5mGPlSWUnAR3wE8w86JWsXRzw2cXvsx4A5WmX6F4vcd-PoabIL5xKydZPSeeP4jKzBQbhdj39MwZpnktSrmClGLd6KdRU2Xfu0l5epLjt_Kjl6q_wtrMQ4WIpr2IKf4NSVcDR3u3y8KM229FnsnB0SLEwaNTLgNvRxAKBHHCaT4IO1Kz05PrTLSYi98QjgbSc4biFj95sw7dPLcfFsmNOq8G1mhQEpSDzLTfccD72XxW4rfkaeWMtGD101_Fl-sePzGYr4KMfShLjWnVS56MRJuWGLponO6HskD226sze9G31XvH5h5Cv4QzsmEgmT_EM09Mxzwrep4RTthLqhkQeyrkHXo_scAsRDiGxlXuLS99MHvgTzV-G55iDUEF7rFeymoNGhuL4OAynxKLrI9T5kxxhbdXAdCkDIeLYW_Ot48A6IlE8J7Y2S4oHxbbFeYNs4i-26VV_GN53k33PtKryUDlibNBhiS5COogVfclwBQQ7dV4RRFOmIIfWm7vAU_h2Wq4lankAswv7vrWJs1AR48y8Qw_iRwB2dZ_s4fnME58119KwrNcoLiFL5ZFnRg-oeAYxhLq--GCEuoFfggb1Cd1JBxlV3RnnqPxXFLlgohJKcM5DQUb1rRLDBUyU-PCxnUwYnHhgX8K72FwDAuTpjukPqfE118n4KlPLkAXRGOyyBFY6rTyubRMdUlH-p9u99c_27er3BAQ_W_TSNW64uxr2WKPkjpe5lfKCL7Q3X40u0un_Vf9qNlr288pYv1VFb9b4jnxVphguzaDvWIvU-HwQb9hEHTZHO78BMFRjuIdnhBSQdhPtjedgA0rIb0TjQHBu6MgiBEoPCPtLeH98woBKKLIrcdtgQ-5yz1-ObNEO5GfrDpr84v-BU-wgScg6pkVEMFkaltw_1UB8QK_yUKcbdK05-yjsnaew9YesDvPOQr9d7QOzd8GkINposftp2T44fyRE4JwT7H4lwYvfiUcQy8mftq7X9m2Xv9oVVTQnE_IHWSg7ZJ5EewHMhm_IjHfSjwP6c=) and Spotify\n(https://www.globenewswire.com/Tracker?data=TJJgICgwctmMYocEqleIdH344z0D0EMKi0HhXJDq-SE6O9rjLqXHYm_MZJiZQjgZ4gEMNNo1vRXSBtR62J-huDW2LVJ1afNetDWnKrzYbyNz6R_LbDbWwVSgt0-UNoB7tTG-MtKuXjIIgz9HrLtDo8dehmPqo--WZJ2cAPJN_fzgdheefg0HHZTvGQHRY3LV-Hq3df3fgVpCEcXYORH-xFZOIw6mtliEhQN1RYfbE2UgeCeMeUndX9fvfbHlOgl9_BcpREeuppZ13_O0yinfUb4gy9WXDAOCNr-ctZptrT2EE0UoeskJCOnIMpmr6jZdPA-PEhIorLRye_sE8bqEARpFofPpDh42CFZmxNK81nIFI0w2GcDcpFW4KtWJC_a37p7BYDqsu8Vt0hXPzWwbcQ3mwg_hJz2J70MOFPK6ZyRpXVQBfcCd3Cz3vShSKXXoiWzFyJNDSSSSR-axsq-AN0NxbtiT4FDeg-MQO-xUZbcG4jAkimfAZwvXN8saVJ1DWJQjLSg8DOA8K6VnTd-bq4vcm6m_gh-0HQ8XxbrVdax-dbc478SC0WdQ1zl13SVEb_aHKkYXz5SqjKt_CX7VkjLxNQloOgK7FIVKA5OPEFFbN1NWs8s4qGK3FmPvVlSkIiAsOLd1KuU_yc8x30_rogCsArGXJ5Lt_1SeyErDJuxJwcp14URzARWtpWSI81sw-BYbfACrTyvmpnrGrJ82k9VQTb4NgwyLIRVSPSY8cXAYxIWitBuC1eRQW0Y0YNSGhxnBpmB9mfCUqpm9X2Sh1wrYmYXLxMqCHsbXMmj9e9MBeikekfSlZUO8Xsg9GNw5sb1FPa2YP182_ZlFQ-DeL14QKw3KfsWsvQVfwEGJMUvCoeql9lVby0CIU1-IFhXAxU77TwnnuF_rp2K7iiUueRv0IPKwGOQfeLaB32ksyZym_b5mv4w2iTSZwBTKzyl0Jrn33tagoV20-VdjvRIgAAdiOt5FUbPqz_l1qLGqpIwdQg1lpC_5zWRGHnTs9cAEhpSBt0jdlh5ZRLx1RfHUwMn4gdR66PlCK9oqXfFaw8xugPdlAw5G8HE4AbOXBREsjZ7ojHdS7a1SULPYFT5sHu5lBnt9sFqiYeD82XoxWSD3198Xlg7lJ5_2k8isg_bkt7Bhj8Iz6430OySR7Cm9kLvOAE8yNg7sGc_bx4BDUnWaCqPyQphbk0esB1_fH1LBfGjUxj51ilqcHACEKpQaTT159lLDGrUW5gTTC_J892sYzPJQwPhtvZd4Tjq4S8sQFTJ7t2Nr3LReZWaTbFr3wJOBYI7sOqpg8jlr52PjeceBmrTYCGFsLXFxe_XWZmlrkOsRQqdJXAEFO7HZO3hTz8wA_qA9fLAhLMNmT-NsAxxOqgKtMP63oWQ88lDdvMnULdJbCNbxBsjfsLlHdDsTGFPsKtRlSd0r6jIV0FIl1fXrCVjC6wslXFe5r-gE_nII-keKmNV-emmt9UXZWpVO3YWsPhU4-FXPzTz6011sSYXvrDIDaHmalZac2KY6HUfYGweIMMfGWpJI3UtLY1wtTzdzYtoRH2AaLhHS_1wOk5EVF3-V8oIW5Z006rNUxhveWUhDmnwMkWbghuWBygYAvg==). \n\nSafe Harbor Statement \nThis press release includes forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. All statements, other\nthan statements of historical fact, are forward-looking statements. We\ngenerally identify forward-looking statements by using words like\n“anticipate,” “believe,” “continue,” “could,” “estimate,”\n“expect,” “forecast,” “goal,” “intend,” “may,” “plan,”\n“should,” “will,” “would,” and similar expressions or variations\nthereof, or the negative thereof, but these terms are not the exclusive means\nof identifying such statements. Forward-looking statements are based on our\ncurrent intentions, beliefs, and expectations regarding future events based on\ninformation that is currently available. We cannot guarantee that any\nforward-looking statement will be accurate. Readers should realize that if\nunderlying assumptions prove inaccurate or if known or unknown risks or\nuncertainties materialize, actual results could differ materially from our\nexpectations. Readers are, therefore, cautioned not to place undue reliance on\nany forward-looking statement. Any forward-looking statement speaks only as of\nthe date of this press release, and, except as required by law, we do not\nundertake to update any forward-looking statement to reflect new information,\nevents, or circumstances. Readers should consider this cautionary statement,\nas well as the risk factors identified in our periodic reports filed with\nthe U.S. Securities and Exchange Commission, when evaluating our\nforward-looking statements. \n\nInvestor Contact:\nRichard S. Lindahl\nExecutive Vice President, CFO\nlindahlr@ebsi.com\n\nMedia Contact:\nAssal Hellmer\nVice President, Communications\nmediarelations@ebsi.com\n\n(1)Smallpox as a Weapon for Bioterrorism\n(https://www.globenewswire.com/Tracker?data=dDCF-ROtUxOmbhVGbrmLtYgEWpa80oLh2U7NRU_0oac09HiTZIU77cgPWmL4aN0VzV2xIEJ_2WulDtNtJ7isftLWLMpp71Co-2aO3X2VU2uaEpaURgoPm524AaaMlBdmI2NQqARRBmx1obgmGfM4_9naTGRp7WJexAwh728of1o=)\n\n(2 )Mpox 2022 to 2025 Update: A Comprehensive Review on Its Complications,\nTransmission, Diagnosis, and Treatment\n(https://www.globenewswire.com/Tracker?data=dMxv5MYUNhZwivavc3X1Igaiyhej_uIXv_wOh6r90KGYyypWk_85q6JORKrrOErlYcMMZLEWSO7nmn_0nvsgyR08Tfr5mgO1BVIkRGbAFCKLTqX0edQfsBWSSsxd5jIaKziyOfosvzqAmmXp_cwqDYl0FU5SrKUnBp2lWUCgtlJORo588itcqdda5dqmBiicQjkX5ebqaMAmXjjz5ZtWIGVAglUZJYK_HWPIONoh1HbbTpx1485fuL9ZwUF3Q4wK)\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/56a9097d-af91-4bcf-8c42-5905e1614ef1)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-18T12:59:00.206630518Z","server_sent_at_ms":1779109140206},"received_at":"2026-05-18T12:59:00.364Z","source_url":null},"analysis":{"id":"27313","press_release_id":"37870","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"regulatory","narrative":"Emergent BioSolutions announced that the Saudi Food and Drug Authority (SFDA) has approved ACAM2000 for the prevention of smallpox and mpox in high-risk individuals.\n\nThis marks the first Emergent product licensed by the SFDA, signaling expanded government adoption in the Gulf region.\n\nThe approval follows a recent expanded indication approval in Singapore, reinforcing the global regulatory momentum for the company's biodefense portfolio.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Emergent secures first SFDA license for ACAM2000, expanding biodefense footprint in the Middle East."},"keyFigures":{"drugName":"ACAM2000","customDimensions":{"global_mpox_cases":"137,000","global_mpox_deaths":"300"}},"quotedText":"ACAM2000® is the first Emergent product to be licensed by the SFDA and demonstrates the company’s intent to collaborate with governments in the Gulf region and around the world as awareness and adoption of biodefense preparedness strategies continues to increase around the world.","namedEntities":{"people":[{"name":"Simon Lowry","role":"Chief Medical Officer"},{"name":"Richard S. Lindahl","role":"Executive Vice President, CFO"},{"name":"Assal Hellmer","role":"Vice President, Communications"}],"products":["ACAM2000","Smallpox and Mpox (Vaccinia) Vaccine, Live"],"companies":[{"name":"Emergent BioSolutions","ticker":"EBS","relationship":"filer"},{"name":"Saudi Food and Drug Authority","relationship":"regulator"},{"name":"Health Sciences Authority","relationship":"regulator"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"SFDA approval for ACAM2000 in Saudi Arabia represents a new market entry for the company's lead biodefense asset. It is a positive regulatory milestone but not a binary FDA approval event, and the commercial impact is incremental rather than transformative."},"tickerRelevance":{"others":[],"primary":"EBS"},"globalImportance":45,"audienceRelevance":50,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"regulatory_approval_international","sectorWeight":"high","householdBrandBoost":"low","retailFavoriteBoost":"low"}},"event_type":"regulatory","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"Emergent BioSolutions announced that the Saudi Food and Drug Authority (SFDA) has approved ACAM2000 for the prevention of smallpox and mpox in high-risk individuals.\n\nThis marks the first Emergent product licensed by the SFDA, signaling expanded government adoption in the Gulf region.\n\nThe approval follows a recent expanded indication approval in Singapore, reinforcing the global regulatory momentum for the company's biodefense portfolio.","key_figures":{"drugName":"ACAM2000","customDimensions":{"global_mpox_cases":"137,000","global_mpox_deaths":"300"}},"named_entities":{"people":[{"name":"Simon Lowry","role":"Chief Medical Officer"},{"name":"Richard S. Lindahl","role":"Executive Vice President, CFO"},{"name":"Assal Hellmer","role":"Vice President, Communications"}],"products":["ACAM2000","Smallpox and Mpox (Vaccinia) Vaccine, Live"],"companies":[{"name":"Emergent BioSolutions","ticker":"EBS","relationship":"filer"},{"name":"Saudi Food and Drug Authority","relationship":"regulator"},{"name":"Health Sciences Authority","relationship":"regulator"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-18T12:59:27.276Z","global_importance":45,"audience_relevance":50,"importance_components":{"tickerTier":"mid-cap","eventGravity":"regulatory_approval_international","sectorWeight":"high","householdBrandBoost":"low","retailFavoriteBoost":"low"}},"durationMs":26893,"modelName":"george-droid-qwen-72b"}}